Back

Impact of evolocumab on coronary plaque stratified by very high-risk ASCVD status: a YELLOW III sub study

31 August 2026 (09:15 - 10:00)
Organised by: Logo
Congress Presentation Part of: Implementing novel lipid‑lowering therapies Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Pruthvi C Revaiah

New York (United States of America)

5 More presentations in this session

Presentation thumbnail
The nocebo effect in statin therapy: clinical implications for adherence and cardiovascular outcomes
Doctor M. Sargsyan (Yerevan, AM)
Abstract
Presentation thumbnail
Comparative effectiveness of lipid-lowering regimens for achieving ESC LDL-cholesterol targets in acute coronary syndrome: a real-world cohort analysis
Doctor A. Romiou (Marousi, GR)
Abstract
Presentation thumbnail
Variability in lipoprotein(a) measurements in ODYSSEY OUTCOMES: is one-and-done testing sufficient?
Professor P. Steg (Paris, FR)
Abstract
Presentation thumbnail
Nationwide implementation of PCSK9--targeted therapies after myocardial infarction and ischemic stroke: structural barriers and disparities in a universal healthcare system
Assistant Professor P. Sedova (Brno, CZ)
Abstract
Presentation thumbnail
Atorvastatin for prevention of chemotherapy-induced cardiotoxicity: a 5-year propensity-matched cohort study of 800 patients
Doctor R. Rascon Sabido (Veracruz, MX)
Abstract

Access the full session

Session thumbnail
Implementing novel lipid‑lowering therapies

The Event

Event poster

ESC Congress 2026

31 August 2026 09:15 CET
You may be interested in
thumbnail
Congress Presentation
Effect of PCSK9 inhibitors on coronary plaque: a meta-analysis and trial sequential analysis
1 September 2025
thumbnail
Congress Presentation
Effects of combining coronary calcium score with treatment on plaque progression in familial coronary artery disease: CAUGHT-CAD RCT
1 September 2025
thumbnail
Congress Presentation
The COR Lipid-Registry: The effectiveness of the strike early and strike strong strategy (SES) in patients with high cardiovascular risk
20 March 2026
thumbnail
Congress Presentation
Carotid plaques stabilization and regression with evolocumab
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources